137 related articles for article (PubMed ID: 2454893)
21. Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.
Lang AB; Fürer E; Larrick JW; Cryz SJ
Infect Immun; 1989 Dec; 57(12):3851-5. PubMed ID: 2509371
[TBL] [Abstract][Full Text] [Related]
22. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.
Pollack M; Callahan LT; Taylor NS
Infect Immun; 1976 Oct; 14(4):942-7. PubMed ID: 825470
[TBL] [Abstract][Full Text] [Related]
24. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
[TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
26. Local IgA and IgG response to intratracheal immunization with Pseudomonas aeruginosa antigens.
Johansen HK; Høiby N
APMIS; 1992 Jan; 100(1):87-90. PubMed ID: 1536724
[TBL] [Abstract][Full Text] [Related]
27. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
Pier GB; Bennett SE
J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
[TBL] [Abstract][Full Text] [Related]
28. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals.
Döring G; Pfeiffer C; Weber U; Mohr-Pennert A; Dorner F
Am J Respir Crit Care Med; 1995 Apr; 151(4):983-5. PubMed ID: 7697276
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.
Pier GB; Thomas DM
J Infect Dis; 1983 Aug; 148(2):206-13. PubMed ID: 6411830
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma.
Campbell WN; Hendrix E; Cryz S; Cross AS
Clin Infect Dis; 1996 Jul; 23(1):179-81. PubMed ID: 8816151
[TBL] [Abstract][Full Text] [Related]
32. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
33. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.
Zhang Q; Choo S; Everard J; Jennings R; Finn A
Infect Immun; 2000 May; 68(5):2692-7. PubMed ID: 10768961
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children.
Ahmed A; Li J; Shiloach Y; Robbins JB; Szu SC
J Infect Dis; 2006 Feb; 193(4):515-21. PubMed ID: 16425130
[TBL] [Abstract][Full Text] [Related]
35. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB
FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219
[TBL] [Abstract][Full Text] [Related]
36. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
37. [Protective artificial polysaccharide-protein antigens made from the O-specific polysaccharides of Pseudomonas aeruginosa bacteria of the immunotypes 1, 2 and 7].
Kul'shin VA; Antsiferova NG; Moroz AF; Dmitriev BA
Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):69-71. PubMed ID: 2464262
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
Welch PG; Fattom A; Moore J; Schneerson R; Shiloach J; Bryla DA; Li X; Robbins JB
J Am Soc Nephrol; 1996 Feb; 7(2):247-53. PubMed ID: 8785394
[TBL] [Abstract][Full Text] [Related]
39. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.
Gilleland HE; Gilleland LB; Matthews-Greer JM
Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440
[TBL] [Abstract][Full Text] [Related]
40. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.
Sorensen RU; Leiva LE; Giangrosso PA; Butler B; Javier FC; Sacerdote DM; Bradford N; Moore C
Pediatr Infect Dis J; 1998 Aug; 17(8):685-91. PubMed ID: 9726341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
